vs
Side-by-side financial comparison of Bausch Health Companies Inc. (BHC) and Fox Corporation (Class A) (FOXA). Click either name above to swap in a different company.
Fox Corporation (Class A) is the larger business by last-quarter revenue ($5.2B vs $2.8B, roughly 1.9× Bausch Health Companies Inc.). Fox Corporation (Class A) runs the higher net margin — 4.8% vs -3.7%, a 8.5% gap on every dollar of revenue. On growth, Bausch Health Companies Inc. posted the faster year-over-year revenue change (9.3% vs 2.0%). Bausch Health Companies Inc. produced more free cash flow last quarter ($403.0M vs $-791.0M). Over the past eight quarters, Fox Corporation (Class A)'s revenue compounded faster (22.6% CAGR vs 14.0%).
Bausch Health Companies Inc. is a global, diversified American-Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic ph...
Fox Corporation, commonly known as Fox Corp or Fox, is an American multinational mass media company headquartered at 1211 Avenue of the Americas in Midtown Manhattan with offices also in Burbank, California. Named after William Fox and incorporated in Delaware, it was formed as a spin-off of 21st Century Fox's television broadcasting, news, and sports assets on March 19, 2019. 21CF went defunct the next day. The company is controlled by Lachlan Murdoch through a family trust with 36% voting s...
BHC vs FOXA — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $2.8B | $5.2B |
| Net Profit | $-103.0M | $247.0M |
| Gross Margin | — | — |
| Operating Margin | 17.0% | 6.2% |
| Net Margin | -3.7% | 4.8% |
| Revenue YoY | 9.3% | 2.0% |
| Net Profit YoY | -205.1% | -36.3% |
| EPS (diluted) | $-0.30 | $0.52 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.8B | $5.2B | ||
| Q3 25 | $2.7B | $3.7B | ||
| Q2 25 | $2.5B | $3.3B | ||
| Q1 25 | $2.3B | $4.4B | ||
| Q4 24 | $2.6B | $5.1B | ||
| Q3 24 | $2.5B | $3.6B | ||
| Q2 24 | $2.4B | $3.1B | ||
| Q1 24 | $2.2B | $3.4B |
| Q4 25 | $-103.0M | $247.0M | ||
| Q3 25 | $179.0M | $609.0M | ||
| Q2 25 | $148.0M | $719.0M | ||
| Q1 25 | $-58.0M | $354.0M | ||
| Q4 24 | $98.0M | $388.0M | ||
| Q3 24 | $-85.0M | $832.0M | ||
| Q2 24 | $10.0M | $320.0M | ||
| Q1 24 | $-64.0M | $704.0M |
| Q4 25 | 17.0% | 6.2% | ||
| Q3 25 | 23.1% | 21.4% | ||
| Q2 25 | 17.5% | 29.2% | ||
| Q1 25 | 12.2% | 10.8% | ||
| Q4 24 | 21.8% | 10.1% | ||
| Q3 24 | 12.7% | 31.2% | ||
| Q2 24 | 16.2% | 14.6% | ||
| Q1 24 | 13.1% | 27.9% |
| Q4 25 | -3.7% | 4.8% | ||
| Q3 25 | 6.7% | 16.3% | ||
| Q2 25 | 5.8% | 21.9% | ||
| Q1 25 | -2.6% | 8.1% | ||
| Q4 24 | 3.8% | 7.6% | ||
| Q3 24 | -3.4% | 23.3% | ||
| Q2 24 | 0.4% | 10.3% | ||
| Q1 24 | -3.0% | 20.4% |
| Q4 25 | $-0.30 | $0.52 | ||
| Q3 25 | $0.48 | $1.32 | ||
| Q2 25 | $0.40 | $1.57 | ||
| Q1 25 | $-0.16 | $0.75 | ||
| Q4 24 | $0.24 | $0.81 | ||
| Q3 24 | $-0.23 | $1.78 | ||
| Q2 24 | $0.03 | $0.68 | ||
| Q1 24 | $-0.17 | $1.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3B | — |
| Total DebtLower is stronger | $20.8B | — |
| Stockholders' EquityBook value | $-554.0M | $10.9B |
| Total Assets | $26.4B | $21.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.7B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $719.0M | — | ||
| Q2 24 | $595.0M | — | ||
| Q1 24 | $733.0M | — |
| Q4 25 | $20.8B | — | ||
| Q3 25 | $21.0B | $6.6B | ||
| Q2 25 | $21.7B | $6.6B | ||
| Q1 25 | $21.5B | $7.2B | ||
| Q4 24 | $21.6B | $7.2B | ||
| Q3 24 | $21.5B | $7.2B | ||
| Q2 24 | $21.7B | $7.2B | ||
| Q1 24 | $22.1B | $7.2B |
| Q4 25 | $-554.0M | $10.9B | ||
| Q3 25 | $-565.0M | $12.2B | ||
| Q2 25 | $-764.0M | $12.0B | ||
| Q1 25 | $-1.2B | $11.5B | ||
| Q4 24 | $-1.3B | $11.5B | ||
| Q3 24 | $-1.2B | $11.3B | ||
| Q2 24 | $-1.2B | $10.7B | ||
| Q1 24 | $-1.1B | $10.6B |
| Q4 25 | $26.4B | $21.5B | ||
| Q3 25 | $26.8B | $22.8B | ||
| Q2 25 | $27.3B | $23.2B | ||
| Q1 25 | $26.4B | $23.4B | ||
| Q4 24 | $26.5B | $23.0B | ||
| Q3 24 | $26.5B | $22.5B | ||
| Q2 24 | $26.5B | $22.0B | ||
| Q1 24 | $26.9B | $21.7B |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.54× | ||
| Q2 25 | — | 0.55× | ||
| Q1 25 | — | 0.62× | ||
| Q4 24 | — | 0.63× | ||
| Q3 24 | — | 0.64× | ||
| Q2 24 | — | 0.67× | ||
| Q1 24 | — | 0.68× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $495.0M | $-669.0M |
| Free Cash FlowOCF − Capex | $403.0M | $-791.0M |
| FCF MarginFCF / Revenue | 14.4% | -15.3% |
| Capex IntensityCapex / Revenue | 3.3% | 2.4% |
| Cash ConversionOCF / Net Profit | — | -2.71× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $495.0M | $-669.0M | ||
| Q3 25 | $405.0M | $-130.0M | ||
| Q2 25 | $289.0M | $1.5B | ||
| Q1 25 | $211.0M | $2.0B | ||
| Q4 24 | $601.0M | $-362.0M | ||
| Q3 24 | $405.0M | $158.0M | ||
| Q2 24 | $380.0M | $899.0M | ||
| Q1 24 | $211.0M | $1.5B |
| Q4 25 | $403.0M | $-791.0M | ||
| Q3 25 | $314.0M | $-234.0M | ||
| Q2 25 | $190.0M | $1.4B | ||
| Q1 25 | $96.0M | $1.9B | ||
| Q4 24 | $495.0M | $-436.0M | ||
| Q3 24 | $334.0M | $94.0M | ||
| Q2 24 | $302.0M | $787.0M | ||
| Q1 24 | $129.0M | $1.4B |
| Q4 25 | 14.4% | -15.3% | ||
| Q3 25 | 11.7% | -6.3% | ||
| Q2 25 | 7.5% | 42.4% | ||
| Q1 25 | 4.2% | 44.4% | ||
| Q4 24 | 19.3% | -8.6% | ||
| Q3 24 | 13.3% | 2.6% | ||
| Q2 24 | 12.6% | 25.5% | ||
| Q1 24 | 6.0% | 40.4% |
| Q4 25 | 3.3% | 2.4% | ||
| Q3 25 | 3.4% | 2.8% | ||
| Q2 25 | 3.9% | 3.6% | ||
| Q1 25 | 5.1% | 1.7% | ||
| Q4 24 | 4.1% | 1.5% | ||
| Q3 24 | 2.8% | 1.8% | ||
| Q2 24 | 3.2% | 3.6% | ||
| Q1 24 | 3.8% | 2.4% |
| Q4 25 | — | -2.71× | ||
| Q3 25 | 2.26× | -0.21× | ||
| Q2 25 | 1.95× | 2.10× | ||
| Q1 25 | — | 5.69× | ||
| Q4 24 | 6.13× | -0.93× | ||
| Q3 24 | — | 0.19× | ||
| Q2 24 | 38.00× | 2.81× | ||
| Q1 24 | — | 2.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
FOXA
| Television Segment | $2.9B | 57% |
| Distribution | $1.2B | 22% |
| Other | $621.0M | 12% |
| Advertising | $491.0M | 9% |
